Brain metastasis from renal cell carcinoma: Presentation, recurrence, and survival

Cancer

Volumn 113, Issue 7, 2008, Pages 1641-1648

  Shuch, Brian ^a   La Rochelle, Jeff C ^a   Klatte, Tobias ^a   Riggs, Stephen B ^a   Liu, Weiqing ^a   Kabbinavar, Fairooz F ^a   Pantuck, Allan J ^a   Belldegrun, Arie S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brain metastasis; Kidney cancer; Radiosurgery; Renal cell cancer

Indexed keywords

ARTICLE; BRAIN TUMOR; CRANIOTOMY; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR RECURRENCE;

BRAIN NEOPLASMS; CARCINOMA, RENAL CELL; CRANIOTOMY; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 54049086165     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23769     Document Type: Article

References (26)

1. Sheehan JP, Sun MH, Kondziolka D, et al. Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg. 2003;98:342-349. (Pubitemid 36151030)
2. Sandock DS, Seftel AD, Resnick MI. A new protocol for the followup of renal cell carcinoma based on pathological stage. J Urol. 1995;154:28-31.
3. Ljungberg B, Alamdari FI, Rasmuson T, et al. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int. 1999;84:405-411. (Pubitemid 29419406)
4. Levy DA, Slaton JW, Swanson DA, et al. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol. 1998;159:1163-1167. (Pubitemid 28172785)
5. Bucci L, Giannini A, Bellotti R, et al. [Role of hypernephroma in a case of intracerebral hemorrhage as a 1st sign of metastasis. Case report.] Riv Neurol. 1986;56:325-335.
6. Bitoh S, Hasegawa H, Ohtsuki H, et al. Cerebral neoplasms initially presenting with massive intracerebral hemorrhage. Surg Neurol. 1984;22:57-62. (Pubitemid 14123105)
7. Mori Y, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for brain metastasis from renal cell carcinoma. Cancer. 1998;83:344-353. (Pubitemid 28317815)
8. Muacevic A, Kreth FW, Mack A, et al. Stereotactic radiosurgery without radiation therapy providing high local tumor control of multiple brain metastases from renal cell carcinoma. Minim Invasive Neurosurg. 2004;47:203-208. (Pubitemid 39222818)
9. Hoshi S, Jokura H, Nakamura H, et al. Gamma-knife radiosurgery for brain metastasis of renal cell carcinoma: results in 42 patients. Int J Urol. 2002;9:618-625; discussion 626; author reply 627.
10. Seaman EK, Ross S, Sawczuk IS. High incidence of asymptomatic brain lesions in metastatic renal cell carcinoma. J Neurooncol. 1995;23:253-256.
11. Seute T, Leffers P, Wilmink JT, et al. Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy. J Clin Oncol. 2006;24:2079-2083. (Pubitemid 46622118)
12. Wronski M, Arbit E, Russo P, et al. Surgical resection of brain metastases from renal cell carcinoma in 50 patients. Urology. 1996;47:187-193. (Pubitemid 26075272)
13. Lam JS, Shvarts O, Leppert JT, et al. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol. 2005;174:466-472; discussion 472; quiz 801.
14. Bukowski RM, Young J, Goodman G, et al. Polyethylene glycol conjugated interleukin-2: clinical and immunologic effects in patients with advanced renal cell carcinoma. Invest New Drugs. 1993;11:211-217. (Pubitemid 23277244)
15. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281. (Pubitemid 46849157)
16. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124. (Pubitemid 46089672)
17. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134. (Pubitemid 46089673)
18. National Comprehensive Cancer Network. Central nervous system cancers. In: NCCN Clinical Practice Guidelines in Oncology. Version 1. Fort Washington, PA: National Comprehensive Cancer Network; 2008.
19. Pan J, Burdick MD, Belperio JA, et al. CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J Immunol. 2006;176:1456-1464. (Pubitemid 43134288)
20. Guirguis LM, Yang JC, White DE, et al. Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother. 2002;25:82-87. (Pubitemid 34052838)
21. Figlin R, Gitlitz B, Franklin J, et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am. 1997;3(suppl 1):S92-S97.
22. Walther MM, Yang JC, Pass HI, et al. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol. 1997;158:1675-1678. (Pubitemid 27433129)
23. Chiu CH, Tsai CM, Chen YM, et al. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer. 2005;47:129-138. (Pubitemid 39643250)
24. Ceresoli GL, Cappuzzo F, Gregorc V, et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol. 2004;15:1042-1047. (Pubitemid 39089780)
25. Thibault F, Billemont B, Rixe O. Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy. J Neurooncol. 2008;86:243-244. (Pubitemid 350263426)
26. Massard C, Zonierek J, Laplanche A, Schwartz B, Szczylik C, Escudier B. Incidence of brain metastasis in advanced renal cell carcinoma among patients randomized in a phase III trial of sorafenib, an oral multi-kinase inhibitor. Ann Oncol. 2006;17(S):1X148-1X149. Abstract 454P.